Integrated Wealth Concepts LLC purchased a new position in Cerus Co. (NASDAQ:CERS – Get Rating) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 20,557 shares of the biotechnology company’s stock, valued at approximately $109,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of CERS. ARK Investment Management LLC lifted its holdings in shares of Cerus by 5.5% during the 2nd quarter. ARK Investment Management LLC now owns 17,111,062 shares of the biotechnology company’s stock worth $84,700,000 after acquiring an additional 897,215 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Cerus by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 9,042,411 shares of the biotechnology company’s stock worth $49,643,000 after acquiring an additional 219,535 shares during the period. Wasatch Advisors Inc. lifted its holdings in shares of Cerus by 2.9% during the 1st quarter. Wasatch Advisors Inc. now owns 8,425,608 shares of the biotechnology company’s stock worth $46,257,000 after acquiring an additional 236,787 shares during the period. State Street Corp lifted its holdings in shares of Cerus by 4.3% during the 1st quarter. State Street Corp now owns 4,634,744 shares of the biotechnology company’s stock worth $25,445,000 after acquiring an additional 193,036 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Cerus by 927.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,986,492 shares of the biotechnology company’s stock worth $15,799,000 after acquiring an additional 2,695,901 shares during the period. 84.72% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Cerus news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the business’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $3.91, for a total value of $48,875.00. Following the completion of the transaction, the director now directly owns 113,808 shares of the company’s stock, valued at $444,989.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.33% of the company’s stock.
Wall Street Analyst Weigh In
Cerus Trading Up 4.1 %
Shares of CERS stock opened at $4.04 on Wednesday. Cerus Co. has a 12-month low of $3.25 and a 12-month high of $7.36. The company has a market capitalization of $716.78 million, a P/E ratio of -18.36 and a beta of 1.11. The firm has a 50-day moving average price of $3.71 and a 200 day moving average price of $4.60. The company has a quick ratio of 1.44, a current ratio of 1.73 and a debt-to-equity ratio of 0.37.
Cerus Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.